Targeting the Microbiome
Discovering Druggable Targets for Microbiome-Therapeutic Development
Part of the 15th Annual Discovery on Target Conference
September 26-27, 2017 | Westin Copley Place | Boston, MA


The microbiome R&D is an emerging area of science that is starting to prove its importance. A PubMed search on the term “microbiome” yielded 300 citations in 2003, 4,498 citations in 2013, and 29,589 citations in 2017. Basic and applied biomedical research from the Human Microbiome Project and other independent studies prove that a disruption of a stable microbiome ecosystem results in dysbioses. This imbalance leads to chronic disease and health conditions. There is great promise in correlating the microbiome compositions with these diseases and using the microbiome as a tool for therapeutic development.


Cambridge Healthtech Institute’s 3rd Annual Targeting the Microbiome tracks both the scientific and clinical progress being made to discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules as potential treatments for chronic disease and health conditions including inflammation, metabolic disorders, gut disorders, obesity, Type 2 Diabetes, autoimmune disorders, inflammatory bowel disease, neurodevelopmental disorders, and more. Through interactive sessions and panel discussions, leading researchers and thought leaders will explore how the microbiome can become a potential point of intervention to impact progression to disease.